Ceftazidime/avibactam (CAZ-AVI) is a promising novel agent with activity against carbapenem-resistant Enterobacteriaceae (CRE). Here, we describe the dynamic evolution of a KPC-producing Klebsiella pneumoniae (KPC-Kp) infection in a critically ill patient treated with CAZ-AVI-tigecycline combination therapy.
Gaibani, P., Gatti, M., Rinaldi, M., Crovara, C., Lazzarotto, T., Giannella, M., et al. (2021). Suboptimal drug exposure leads selection of different subpopulations of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae in a critically ill patient. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 113, 213-217 [10.1016/j.ijid.2021.10.028].
Suboptimal drug exposure leads selection of different subpopulations of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae in a critically ill patient
Gaibani, Paolo;Gatti, Milo;Rinaldi, Matteo;Lazzarotto, Tiziana;Giannella, Maddalena;Lombardo, Donatella;Viale, Pierluigi;Pea, Federico;Ambretti, Simone
2021
Abstract
Ceftazidime/avibactam (CAZ-AVI) is a promising novel agent with activity against carbapenem-resistant Enterobacteriaceae (CRE). Here, we describe the dynamic evolution of a KPC-producing Klebsiella pneumoniae (KPC-Kp) infection in a critically ill patient treated with CAZ-AVI-tigecycline combination therapy.| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S120197122100816X-main.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione
491.58 kB
Formato
Adobe PDF
|
491.58 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
